10-Q: Nu-Med Plus Reports Q2 2024 Results, Merger with YourSpace America Pending

Nu-Med Plus reports no revenue and a net loss for the second quarter of 2024, while awaiting the completion of the YourSpace America merger.

Summary

• Nu-Med Plus, Inc. reported no revenue for both the three and six months ended June 30, 2024.
• The company experienced a net loss of $17,287 for the three months ended June 30, 2024, and a net loss of $39,112 for the six months ended June 30, 2024.
• Operating expenses decreased to $16,040 for the three months and $36,619 for the six months ended June 30, 2024, primarily due to reduced professional and consulting fees and rent expenses.
• The company's cash balance was $4,041 as of June 30, 2024, down from $6,806 at the end of 2023.
• Nu-Med Plus is in the process of merging with YourSpace America, Inc., with the closing contingent on the completion of YSA's 2023 audit.
• The merger will result in the issuance of preferred stock to YSA shareholders, including Series A and Series X preferred stock.
• The company acknowledges that it needs approximately $1,200,000 in additional funding over the next 12 months to execute its business plan.
• Nu-Med Plus has developed several nitric oxide delivery systems but has not yet submitted them for FDA approval.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including no revenue, net losses, and a need for substantial additional funding. The merger is delayed, and there are risks associated with the company's ability to continue as a going concern. The sentiment is negative due to the company's precarious financial situation and lack of commercial progress.

Positives

• Operating expenses decreased for both the three and six month periods ending June 30, 2024, compared to the same periods in 2023.
• The company is actively pursuing a merger with YourSpace America, which could provide new opportunities and resources.
• Nu-Med Plus has developed several nitric oxide delivery systems, indicating potential for future revenue generation.

Negatives

• The company has no revenue and continues to operate at a loss.
• Cash reserves have decreased significantly.
• The company has a working capital deficiency of $185,863.
• The merger with YourSpace America is contingent on the completion of YSA's audit, creating uncertainty.
• The company needs substantial additional funding to continue operations and product development.
• There is no guarantee that the company will be able to obtain the necessary funding.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient funds.
• The merger with YourSpace America may not be completed if the audit is delayed or unfavorable.
• The company's products have not yet received FDA approval, which is a lengthy and expensive process.
• The company relies on a small group of investors for funding, which is a significant risk.
• The company faces competition in the medical device field.
• The company's products are still in the development stage and may not be commercially viable.

Future Outlook

The company anticipates needing $1,200,000 in additional financing over the next 12 months to cover corporate overhead and product development. The company does not anticipate any revenue in the foreseeable future as products are still in development.

Management Comments

• Management believes that with the further refinement of our formulation, we can make and filter medical grade nitric oxide gas with minimal amounts of nitrogen dioxide.
• Management anticipates that selling our units earlier into the market as laboratory equipment or to international groups will pave the way for sales of our medical delivery devices.
• Management believes that there is ample room for a competitive response from NU-MED using on site generated nitric oxide at a lower cost to penetrate the market.

Industry Context

The company operates in the medical device field, specifically focusing on nitric oxide delivery systems. The market for nitric oxide therapies is growing, but the company faces competition from established players. The company's focus on reducing the cost of nitric oxide delivery could provide a competitive advantage.

Comparison to Industry Standards

• Nu-Med Plus is an early-stage company with no revenue, which is not uncommon for companies in the medical device development phase.
• The company's reliance on external funding is typical for companies in this stage, but the lack of a clear path to profitability is a concern.
• The company's focus on nitric oxide delivery is aligned with a growing trend in medical therapies, but the company's products are not yet approved for commercial use.
• Compared to companies like Mallinckrodt, which markets Inomax, Nu-Med Plus is significantly smaller and earlier in its development cycle.
• The company's lack of revenue and reliance on external funding is similar to other early-stage medical device companies, but the company's specific technology and market focus are unique.

Management Changes

Related Party Transactions

• The company has accounts payable to a related party totaling $68,586 as of June 30, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and need for additional funding.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers are not yet impacted as the company's products are still in development.
• Suppliers and creditors may be at risk due to the company's financial difficulties.

Next Steps

• Complete the audit of YourSpace America's financial statements for the year ended December 31, 2023.
• Close the merger transaction with YourSpace America.
• Secure additional funding of approximately $1,200,000 over the next 12 months.
• Continue development of nitric oxide delivery systems.
• Seek FDA approval for the company's products.

Key Dates

Keywords

nitric oxide, medical device, merger, YourSpace America, FDA approval, funding, preferred stock, financial statements, operating expenses, net loss